Company: NIVFW
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001213900-25-079717
Chunk: 90

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-22
Form: DRS
Chunk 90
---
% tariff on all steel and aluminum imports, beginning in March 2025. On February 13, 2025, President Trump ordered
his trade advisers to come up with “reciprocal” tariffs on U.S. trade partners to retaliate against taxes, tariffs, regulations
and subsidies and on April 2, 2025, announced new tariffs on many U.S. trading partners, including a universal baseline tariff of 10%
on all imported goods, and country specific tariffs such as an additional 34% tax on imports from China (leading to an effective rate
of 54% when combined with existing tariffs) and 20% on products from the E.U. Specific products that are being tariffed, such as automobiles,
were to be exempted from the new tariffs, and tariffs on products such as pharmaceutical drugs were to be announced at a later date. Following
a period of market turbulence, on April 9, 2025, President Trump announced a 90-day pause to the tariffs announced on April 2, 2025 for
most countries. Countries subject to the pause on the tariffs are still to be subject to the baseline 10% tariff. This consequently lowers
the tariff rate for the E.U., Japan, and South Korea, among other countries. However, U.S. President Trump announced an increased tariff
rate against Chinese imports of a minimum 145%. These and other tariffs and countermeasures could increase the cost of equipment necessary
for our operations, disrupt global supply chains and create additional operational challenges. Additionally, ongoing trade tensions and
uncertainty regarding future trade policies could negatively impact global economic conditions and consumer confidence, further affecting
our business performance.

Any litigation against NewGenIvf could be costly and time-consuming to defend and could harm its business, financial condition and results of operations.

NewGenIvf has in the past
and may in the future become subject to regulatory actions, litigation, disputes, or claims of various types, legal proceedings and claims
that arise in the ordinary course of business, such as claims brought by its clients or vendors in connection with commercial disputes
or employment claims made by its current or former employees, as well as claims brought by relevant regulatory authorities or NewGenIvf’s
competitors, patients, employees, or other third parties against NewGenIvf. NewGenIvf is unable to predict the outcome of any of these
legal proceedings. Such regulatory actions, disputes, allegations, complaints, or legal proceedings may damage NewGenI